Krabbe, Laura-Maria
Margulis, Vitaly
Schrader, Andres Jan
Shariat, Shahrokh F.
Gust, Kilian M.
Boegemann, Martin
Article History
Received: 28 March 2018
Accepted: 25 May 2018
First Online: 8 June 2018
Compliance with ethical standards
:
: LMK, VM, AJS and KMG have no conflict of interest. SFS holds patents (Method to determine prognosis after therapy for prostate cancer, granted 2002-09-06; Methods to determine prognosis after therapy for bladder cancer, granted 2003-06-19; Prognostic methods for patients with prostatic disease, granted 2004-08-05; Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma, granted 2010-07-20) and has served on the advisory board/as a speaker for Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring`, Ipsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Sanochemia, Sanofi, and Wolf. MB has served on the advisory board/as a speaker for MSD, BMS, Roche, Astra Zeneca, Janssen, Astellas, Amgen, Ipsen, Sanofi, ABX, Eisai, Bayer, Novartis, and Pfizer. As this is a review article, no research involving human participants and/or animals was carried out and no informed consent was needed.